Zoonotic Disease Treatment Market (2025 - 2035)

Zoonotic Disease Treatment Market Size and Share Forecast Outlook 2025 to 2035

Published on August 08, 2025

250 pages

Healthcare

Animal Health Therapeutics

Sabyasachi Ghosh

Key Statistics

Industry Size (2025): USD 46.4 billion
Forecast (2035): USD 82.3 billion
CAGR: 5.9% (2025 to 2035)

About The Report

Methodology

Zoonotic Disease Treatment Market Size and Share Forecast Outlook 2025 to 2035

The Zoonotic Disease Treatment Market is estimated to be valued at USD 46.4 billion in 2025 and is projected to reach USD 82.3 billion by 2035, registering a compound annual growth rate (CAGR) of 5.9% over the forecast period.

Quick Stats for Zoonotic Disease Treatment Market

Zoonotic Disease Treatment Market Industry Value (2025): USD 46.4 billion
Zoonotic Disease Treatment Market Forecast Value (2035): USD 82.3 billion
Zoonotic Disease Treatment Market Forecast CAGR: 5.9%
Leading Segment in Zoonotic Disease Treatment Market in 2025: Rabies (30.5%)
Key Growth Region in Zoonotic Disease Treatment Market: North America, Asia-Pacific, Europe
Top Key Players in Zoonotic Disease Treatment Market: Pfizer Inc., Cadila Healthcare Ltd., AstraZeneca plc, F. Hoffmann‑La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Novartis International AG, Sanofi S.A., BioCryst Pharmaceuticals Inc, Sun Pharmaceuticals Industries Ltd.

Zoonotic Disease Treatment Market Market Value Analysis

Metric	Value
Zoonotic Disease Treatment Market Estimated Value in (2025 E)	USD 46.4 billion
Zoonotic Disease Treatment Market Forecast Value in (2035 F)	USD 82.3 billion
Forecast CAGR (2025 to 2035)	5.9%

Rationale for Segmental Growth in the Zoonotic Disease Treatment Market

The zoonotic disease treatment market is advancing steadily as public health concerns related to animal-to-human infections intensify globally. Increased prevalence of zoonotic diseases alongside rising awareness about early diagnosis and effective treatment is fueling demand for specialized therapies.

Healthcare providers and governments are prioritizing investments in disease control infrastructure and pharmaceutical interventions to curb outbreaks and reduce mortality rates. Innovations in drug development and enhanced surveillance systems have facilitated timely treatment protocols, while integrated efforts between veterinary and human health sectors are strengthening overall response mechanisms.

Looking ahead, growing emphasis on pandemic preparedness, improved diagnostic capabilities, and expanded healthcare access are expected to create sustained growth opportunities. The market’s trajectory is being shaped by the critical need to manage zoonotic infections effectively and prevent spillover events.

Segmental Analysis

The market is segmented by Disease Type, Drug Class, and End User and region. By Disease Type, the market is divided into Rabies, Hepatitis, Tuberculosis, Fever, and Others. In terms of Drug Class, the market is classified into Antibacterial, Antifungal, Antibiotic, and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare, and Others. Regionally, the market is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.

Insights into the Rabies Disease Type Segment

Zoonotic Disease Treatment Market Analysis By Disease Type

When segmented by disease type, rabies is projected to lead the market with a 30.5% revenue share in 2025. This leadership is driven by the disease’s high fatality rate and the urgent requirement for effective post-exposure treatments.

Healthcare systems have been increasingly focused on expanding access to rabies vaccines and immunoglobulins to prevent disease progression following animal bites. Public health campaigns and government immunization programs have elevated awareness, contributing to increased diagnosis and treatment rates.

Additionally, the need for prophylactic treatment in high-risk populations has reinforced the importance of rabies management as a priority within the zoonotic disease treatment landscape. These factors have collectively established rabies as a key focus area, sustaining its significant market share.

Insights into the Antibacterial Drug Class Segment

Zoonotic Disease Treatment Market Analysis By Drug Class

Segmented by drug class, antibacterial treatments are expected to hold a dominant 35.0% share of the market revenue in 2025. The prominence of antibacterials is linked to their broad-spectrum efficacy against numerous bacterial zoonoses, which are commonly encountered in clinical settings.

The widespread use of antibacterial agents for treating infections such as leptospirosis, plague, and brucellosis has driven demand. Furthermore, investments in developing novel antibacterial formulations and combination therapies have supported sustained growth in this segment.

Hospitals and clinics have prioritized antibacterials due to their proven effectiveness, well-established treatment guidelines, and availability. This continued reliance on antibacterial drugs has reinforced their leading position within the treatment market.

Insights into the Hospitals End User Segment

Zoonotic Disease Treatment Market Analysis By End User

When segmented by end user, hospitals are expected to account for a leading 42.0% revenue share in 2025. The dominance of hospitals is attributed to their central role in diagnosing and treating zoonotic diseases, often requiring complex clinical management and inpatient care.

Hospitals have invested significantly in specialized infectious disease units and advanced diagnostic technologies to support early detection and timely intervention. The presence of trained healthcare professionals and infrastructure for administering treatments such as intravenous therapies and vaccinations further cements hospitals as the primary setting for zoonotic disease management.

This segment’s leadership reflects the critical nature of hospital-based care in improving patient outcomes and controlling disease spread.

What are the Major Drivers Boosting the Demand for Zoonotic Disease Treatment Market?

Population growth, migration, and rapid urbanization are all factors that could lead to the emergence of new zoonotic diseases in the future. Due to market and production procedures for live food animals, people in urban regions are less familiar with dealing with animals than those in rural settings. The urban population may also reside in overcrowded conditions that aid in the spread of disease.

Increased demand for animal proteins is probably going to result in increased consumption of animal fats, which is going to fuel the market for zoonotic disease treatment. With millions of households owning one or more pets for companionship and entertainment. However, the possibility that some animals may carry pathogens that might infect humans when in contact is anticipated to drive the market for the same.

Which Region Shows Strong Growth Potential in the Zoonotic Disease Treatment Market?

The zoonotic disease treatment market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

North America is the leading region in the global zoonotic disease treatment market owing to the rising population, higher rate of immigration, and rapid urbanization.

Apart from North America, the European zoonotic disease treatment market is also expected to display lucrative growth in the projected years due to the extensive livestock farming and increased consumption of animal fat in country places.

The East Asian region is predicted to show lucrative growth owing to a lack of access to safe drinking water and adequate sanitation services, which could contribute to the development of zoonotic diseases.

Who are the Key Players in the Zoonotic Disease Treatment Market?

Cadila Healthcare Ltd, AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson, Pfizer Inc., Novartis International AG, Sanofi S.A., BioCryst Pharmaceuticals, Inc, Sun Pharmaceuticals Industries, Ltd.

Scope of Report

Report Attributes	Details
Growth Rate	CAGR of 5.9% from 2025 to 2035
Base Year for Estimation	2024
Historical Data	2012 to 2024
Forecast Period	2025 to 2035
Qualitative Units	Revenue in USD Billion, and CAGR from 2025 to 2035
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segment Covered	Disease Type, Drug Class, End User, Region
Region Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East Africa (MEA)
Key Countries Profiled	The USA, Canada, Brazil, Mexico, Germany, The UK, France, Spain, Italy, China, Japan, South Korea, Malaysia, Singapore, Australia, New Zealand, GCC, South Africa, Israel
Key Players	Cadila Healthcare Ltd; AstraZeneca plc; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; Johnson Johnson; Pfizer Inc.; Novartis International AG; Sanofi S.A.; BioCryst Pharmaceuticals, Inc; Sun Pharmaceuticals Industries, Ltd.
Customization	Available Upon Request

Key Segments Covered in the Zoonotic Disease Treatment Market Report

By Disease Type:

Rabies
Hepatitis
Tuberculosis
Fever
Others

By Drug Class:

Antifungal
Antibacterial
Antibiotic
Others

By End User:

Hospitals
Specialty Clinics
Homecare
Others

By Region:

North America
Latin America
Europe
East Asia
South Asia Pacific
The Middle East and Africa (MEA)

Frequently Asked Questions

How big is the zoonotic disease treatment market in 2025?

The global zoonotic disease treatment market is estimated to be valued at USD 46.4 billion in 2025.

What will be the size of zoonotic disease treatment market in 2035?

The market size for the zoonotic disease treatment market is projected to reach USD 82.3 billion by 2035.

How much will be the zoonotic disease treatment market growth between 2025 and 2035?

The zoonotic disease treatment market is expected to grow at a 5.9% CAGR between 2025 and 2035.

What are the key product types in the zoonotic disease treatment market?

The key product types in zoonotic disease treatment market are rabies, hepatitis, tuberculosis, fever and others.

Which drug class segment to contribute significant share in the zoonotic disease treatment market in 2025?

In terms of drug class, antibacterial segment to command 35.0% share in the zoonotic disease treatment market in 2025.

Table of Content

Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
Market Background
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunity
  - Trends
- Scenario Forecast
  - Demand in Optimistic Scenario
  - Demand in Likely Scenario
  - Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
Global Market Analysis 2020 to 2024 and Forecast, 2025 to 2035
- Historical Market Size Value (USD Million) Analysis, 2020 to 2024
- Current and Future Market Size Value (USD Million) Projections, 2025 to 2035
  - Y-o-Y Growth Trend Analysis
  - Absolute $ Opportunity Analysis
Global Market Pricing Analysis 2020 to 2024 and Forecast 2025 to 2035
Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Disease Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Disease Type , 2020 to 2024
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Disease Type , 2025 to 2035
  - Rabies
  - Hepatitis
  - Tuberculosis
  - Fever
  - Others
- Y-o-Y Growth Trend Analysis By Disease Type , 2020 to 2024
- Absolute $ Opportunity Analysis By Disease Type , 2025 to 2035
Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Drug Class
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Drug Class, 2020 to 2024
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Drug Class, 2025 to 2035
  - Antibacterial
  - Antifungal
  - Antibiotic
  - Others
- Y-o-Y Growth Trend Analysis By Drug Class, 2020 to 2024
- Absolute $ Opportunity Analysis By Drug Class, 2025 to 2035
Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By End User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End User, 2020 to 2024
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End User, 2025 to 2035
  - Hospitals
  - Specialty Clinics
  - Homecare
  - Others
- Y-o-Y Growth Trend Analysis By End User, 2020 to 2024
- Absolute $ Opportunity Analysis By End User, 2025 to 2035
Global Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2020 to 2024
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2025 to 2035
  - North America
  - Latin America
  - Western Europe
  - Eastern Europe
  - East Asia
  - South Asia and Pacific
  - Middle East & Africa
- Market Attractiveness Analysis By Region
North America Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
  - By Country
    - USA
    - Canada
    - Mexico
  - By Disease Type
  - By Drug Class
  - By End User
- Market Attractiveness Analysis
  - By Country
  - By Disease Type
  - By Drug Class
  - By End User
- Key Takeaways
Latin America Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
  - By Country
    - Brazil
    - Chile
    - Rest of Latin America
  - By Disease Type
  - By Drug Class
  - By End User
- Market Attractiveness Analysis
  - By Country
  - By Disease Type
  - By Drug Class
  - By End User
- Key Takeaways
Western Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
  - By Country
    - Germany
    - UK
    - Italy
    - Spain
    - France
    - Nordic
    - BENELUX
    - Rest of Western Europe
  - By Disease Type
  - By Drug Class
  - By End User
- Market Attractiveness Analysis
  - By Country
  - By Disease Type
  - By Drug Class
  - By End User
- Key Takeaways
Eastern Europe Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
  - By Country
    - Russia
    - Poland
    - Hungary
    - Balkan & Baltic
    - Rest of Eastern Europe
  - By Disease Type
  - By Drug Class
  - By End User
- Market Attractiveness Analysis
  - By Country
  - By Disease Type
  - By Drug Class
  - By End User
- Key Takeaways
East Asia Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
  - By Country
    - China
    - Japan
    - South Korea
  - By Disease Type
  - By Drug Class
  - By End User
- Market Attractiveness Analysis
  - By Country
  - By Disease Type
  - By Drug Class
  - By End User
- Key Takeaways
South Asia and Pacific Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
  - By Country
    - India
    - ASEAN
    - Australia & New Zealand
    - Rest of South Asia and Pacific
  - By Disease Type
  - By Drug Class
  - By End User
- Market Attractiveness Analysis
  - By Country
  - By Disease Type
  - By Drug Class
  - By End User
- Key Takeaways
Middle East & Africa Market Analysis 2020 to 2024 and Forecast 2025 to 2035, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2020 to 2024
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2025 to 2035
  - By Country
    - Kingdom of Saudi Arabia
    - Other GCC Countries
    - Turkiye
    - South Africa
    - Other African Union
    - Rest of Middle East & Africa
  - By Disease Type
  - By Drug Class
  - By End User
- Market Attractiveness Analysis
  - By Country
  - By Disease Type
  - By Drug Class
  - By End User
- Key Takeaways
Key Countries Market Analysis
- USA
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Canada
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Mexico
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Brazil
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Chile
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Germany
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- UK
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Italy
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Spain
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- France
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- India
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- ASEAN
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Australia & New Zealand
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- China
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Japan
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- South Korea
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Russia
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Poland
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Hungary
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Kingdom of Saudi Arabia
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- Turkiye
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
- South Africa
  - Pricing Analysis
  - Market Share Analysis, 2024
    - By Disease Type
    - By Drug Class
    - By End User
Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
  - By Regional
  - By Disease Type
  - By Drug Class
  - By End User
Competition Analysis
- Competition Deep Dive
  - Pfizer Inc.
    - Overview
    - Product Portfolio
    - Profitability by Market Segments (Product/Age /Sales Channel/Region)
    - Sales Footprint
    - Strategy Overview
      - Marketing Strategy
      - Product Strategy
      - Channel Strategy
  - Cadila Healthcare Ltd.
  - AstraZeneca plc
  - F. Hoffmann‑La Roche AG
  - GlaxoSmithKline plc
  - Johnson & Johnson
  - Novartis International AG
  - Sanofi S.A.
  - BioCryst Pharmaceuticals Inc
  - Sun Pharmaceuticals Industries Ltd.
Assumptions & Acronyms Used
Research Methodology

Request Detailed TOC

List of Tables

Table 1: Global Market Value (USD Million) Forecast by Region, 2020-2035
Table 2: Global Market Value (USD Million) Forecast by Disease Type , 2020-2035
Table 3: Global Market Value (USD Million) Forecast by Drug Class, 2020-2035
Table 4: Global Market Value (USD Million) Forecast by End User, 2020-2035
Table 5: North America Market Value (USD Million) Forecast by Country, 2020-2035
Table 6: North America Market Value (USD Million) Forecast by Disease Type , 2020-2035
Table 7: North America Market Value (USD Million) Forecast by Drug Class, 2020-2035
Table 8: North America Market Value (USD Million) Forecast by End User, 2020-2035
Table 9: Latin America Market Value (USD Million) Forecast by Country, 2020-2035
Table 10: Latin America Market Value (USD Million) Forecast by Disease Type , 2020-2035
Table 11: Latin America Market Value (USD Million) Forecast by Drug Class, 2020-2035
Table 12: Latin America Market Value (USD Million) Forecast by End User, 2020-2035
Table 13: Western Europe Market Value (USD Million) Forecast by Country, 2020-2035
Table 14: Western Europe Market Value (USD Million) Forecast by Disease Type , 2020-2035
Table 15: Western Europe Market Value (USD Million) Forecast by Drug Class, 2020-2035
Table 16: Western Europe Market Value (USD Million) Forecast by End User, 2020-2035
Table 17: Eastern Europe Market Value (USD Million) Forecast by Country, 2020-2035
Table 18: Eastern Europe Market Value (USD Million) Forecast by Disease Type , 2020-2035
Table 19: Eastern Europe Market Value (USD Million) Forecast by Drug Class, 2020-2035
Table 20: Eastern Europe Market Value (USD Million) Forecast by End User, 2020-2035
Table 21: East Asia Market Value (USD Million) Forecast by Country, 2020-2035
Table 22: East Asia Market Value (USD Million) Forecast by Disease Type , 2020-2035
Table 23: East Asia Market Value (USD Million) Forecast by Drug Class, 2020-2035
Table 24: East Asia Market Value (USD Million) Forecast by End User, 2020-2035
Table 25: South Asia and Pacific Market Value (USD Million) Forecast by Country, 2020-2035
Table 26: South Asia and Pacific Market Value (USD Million) Forecast by Disease Type , 2020-2035
Table 27: South Asia and Pacific Market Value (USD Million) Forecast by Drug Class, 2020-2035
Table 28: South Asia and Pacific Market Value (USD Million) Forecast by End User, 2020-2035
Table 29: Middle East & Africa Market Value (USD Million) Forecast by Country, 2020-2035
Table 30: Middle East & Africa Market Value (USD Million) Forecast by Disease Type , 2020-2035
Table 31: Middle East & Africa Market Value (USD Million) Forecast by Drug Class, 2020-2035
Table 32: Middle East & Africa Market Value (USD Million) Forecast by End User, 2020-2035

List of Figures

Figure 1: Global Market Pricing Analysis
Figure 2: Global Market Value (USD Million) Forecast 2020-2035
Figure 3: Global Market Value (USD Million) Share and BPS Analysis by Region, 2025 and 2035
Figure 4: Global Market Y-o-Y Growth Comparison by Region, 2025-2035
Figure 5: Global Market Attractiveness Analysis by Region
Figure 6: North America Market Incremental Dollar Opportunity, 2025-2035
Figure 7: Latin America Market Incremental Dollar Opportunity, 2025-2035
Figure 8: Western Europe Market Incremental Dollar Opportunity, 2025-2035
Figure 9: Eastern Europe Market Incremental Dollar Opportunity, 2025-2035
Figure 10: East Asia Market Incremental Dollar Opportunity, 2025-2035
Figure 11: South Asia and Pacific Market Incremental Dollar Opportunity, 2025-2035
Figure 12: Middle East & Africa Market Incremental Dollar Opportunity, 2025-2035
Figure 13: North America Market Value Share and BPS Analysis by Country, 2025 and 2035
Figure 14: Latin America Market Value Share and BPS Analysis by Country, 2025 and 2035
Figure 15: Western Europe Market Value Share and BPS Analysis by Country, 2025 and 2035
Figure 16: Eastern Europe Market Value Share and BPS Analysis by Country, 2025 and 2035
Figure 17: East Asia Market Value Share and BPS Analysis by Country, 2025 and 2035
Figure 18: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2025 and 2035
Figure 19: Middle East & Africa Market Value Share and BPS Analysis by Country, 2025 and 2035
Figure 20: Global Market - Tier Structure Analysis
Figure 21: Global Market - Company Share Analysis